Trade DBV Technologies SA - DBV CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.017307 %(-€0.87)Trade size with leverage ~ €5,000.00Money from leverage ~€4,000.00Go to platform: -0.01731%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.004915 %(-€0.25)Trade size with leverage ~ €5,000.00Money from leverage ~€4,000.00Go to platform: -0.00492%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: France
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.017307 %
  (-€0.87)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.004915 %
  (-€0.25)

Key Stats

• Prev. Close: 2.36
• Open: 2.36
• 1-Year Change: 38.82%
• Day's Range: 2.36 - 2.4

Trade DBV Technologies SA - DBV

About DBV Technologies SA

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, DBV Technologies SA revenues decreased 49% to $5.7M. Net loss applicable to common stockholders decreased 39% to $98.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development decrease of 31% to $70.1M (expense), Restructuring decrease from $23M (expense) to $920K (income).